Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: Clinical benefit with optimal patient selectionHATA, Akito; KATAKAMI, Nobuyuki; NISHIYAMA, Akihiro et al.Lung cancer. 2011, Vol 74, Num 2, pp 268-273, issn 0169-5002, 6 p.Article

The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung diseaseSHIMIZU, Ryoko; FUJIMOTO, Daichi; OTSUKA, Kojiro et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1159-1166, issn 0344-5704, 8 p.Article

Preexisting interstitial lung disease is inversely correlated to tumor epidermal growth factor receptor mutation in patients with lung adenocarcinomaFUJIMOTO, Daichi; TOMII, Keisuke; OTSUKA, Kyoko et al.Lung cancer. 2013, Vol 80, Num 2, pp 159-164, issn 0169-5002, 6 p.Article

Rebiopsy of Non―Small Cell Lung Cancer Patients With Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: Comparison Between T790M Mutation-Positive and Mutation-Negative PopulationsHATA, Akito; KATAKAMI, Nobuyuki; MATSUMOTO, Takeshi et al.Cancer. 2013, Vol 119, Num 24, pp 4325-4332, issn 0008-543X, 8 p.Article

Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancerHATA, Akito; KATAKAMI, Nobuyuki; NISHIMURA, Takashi et al.Lung cancer. 2011, Vol 72, Num 2, pp 224-228, issn 0169-5002, 5 p.Article